Find A Physician
More on Weill Cornell Researchers Develop New Way To Predict Prostate Cancer Patients' Response to Radiation Therapy
Hospital News
More on Weill Cornell Researchers Develop New Way To Predict Prostate Cancer Patients' Response to Radiation Therapy
- NewYork-Presbyterian/Weill Cornell Research Presented at American Urological Association Meeting
- Can a New PET Imaging Technique More Quickly Predict Response to Ongoing Cancer Treatment?
- Laser May Reduce Prostate Surgery's Sexual Side Effects
- NewYork-Presbyterian Hospital/Columbia University Medical Center Physician-Scientists Present at American Urological Association Annual Meeting
- NewYork-Presbyterian Hospital/Weill Cornell Medical Center Physician-Scientists Present at 2010 American Urological Association Meeting
- Weill Cornell Science Briefs: December 2008-January 2009
Research and Clinical Trials
More on Weill Cornell Researchers Develop New Way To Predict Prostate Cancer Patients' Response to Radiation Therapy
Health Library
More on Weill Cornell Researchers Develop New Way To Predict Prostate Cancer Patients' Response to Radiation Therapy
- Prostate Cancer
- Prostate Cancer: Coping
- Prostate Cancer: Expectant Therapy
- Prostate Cancer: For Family Members
- Prostate Cancer: Psychosocial Factors
- Prostate Cancer: Stages
- Prostate Cancer: Surgery
- Prostate Cancer Grading
- Prostate Cancer in African-American Men
- Prostate Cancer Online Resources
- Prostate Cancer Overview
- Prostate Cancer Radiation Therapy
- Prostate Cancer Risk Factors
- Prostate Cancer Signs and Symptoms
- Prostate Cancer Statistics
- Prostate Cancer Treatment
- Prostate Health: Online Resources
- Prostate Health Glossary
- Prostate Problems: Diagnostic and Evaluation Procedures
Clinical Services
More on Weill Cornell Researchers Develop New Way To Predict Prostate Cancer Patients' Response to Radiation Therapy
- Advanced Radiation Oncology Technologies
- Brachytherapy
- Brain and Spinal Cord Cancer
- Breast Cancer
- Breast Cancer: Partial Breast Irradiation
- Contact Us / Our Locations
- CT Simulation and Treatment Planning
- Digestive System Cancers
- Find a Clinical Trial
- Gynecological Cancers
- Head and Neck Cancer
- Image-Guided Radiotherapy (IGRT)
- IMRT Symposium
- Intensity-Modulated Radiotherapy (IMRT)
- Lung Cancer
- Other Cancers
- Pediatric Cancers
- Prostate Cancer
- Prostate Seed Implants
- Skin Cancer
- Stereotactic Radiosurgery and Gamma Knife®
- Urology
Weill Cornell Researchers Develop New Way To Predict Prostate Cancer Patients' Response to Radiation Therapy
NEW YORK (May 3, 1999)
Doctors treating localized prostate cancer have long been frustrated by not knowing which patients will or will not respond to radiation therapy. A significant proportion of patients fail therapy due to rising post-treatment prostate specific antigen (PSA) levels. To solve this dilemma, researchers at Weill Medical College of Cornell University examined two genetic markers, bcl-2 and p53 in prostate biopisies, and developed a model that will help predict who will fail radiation therapy prior to the onset of treatment.
Results of the study were presented today at the American Urological Association 1999 Annual Meeting in Dallas. The study, led by E. Darracott Vaughan, M.D., and Douglas S. Scherr, M.D., of the Department of Urology at Weill Medical College, is an analysis of the link between two genetic markers, bcl-2 and p53, and patients' response to radiation therapy. Dr. Vaughan and his colleagues found that patients who had high levels of bcl-2 and/or p53 in their prostate biopsies went on to fail radiation therapy for their prostate cancer.
"Molecular markers such as bcl-2 and p53 have the potential to revolutionize the clinical staging system of localized prostate cancer," explains Dr. Vaughan. "There is overwhelming clinical evidence to suggest that patients who overexpress bcl-2 or have accumulation of functionally inactive p53 in their prostate biopsies will be much more likely to fail radiation therapy for their clinically localized prostate cancer," says Dr. Scherr.
These findings allow physicians to determine which patients will fail radiation therapy and may benefit from other treatments. Physicians can utilize this by having pathologists assess a patient's prostate biopsy for the genetic markers bcl-2 and p53.
Along with Drs. Vaughan and Scherr, the Weill Cornell research team includes Dr. Marilda Chung, Assistant Professor of Pathology; Dr. Diane Felsen, Associate Research Professor of Pharmacology in Urology; Dr. Robert Allbright, The Stich-Department of Radiation Oncology; and Dr. Beatrice S. Knudsen, Assistant Professor of Pathology.
